Triantel may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Praziquantel is reported as an ingredient of Triantel in the following countries:
Pyrantel embonate (a derivative of Pyrantel) is reported as an ingredient of Triantel in the following countries:
International Drug Name Search
Amoxibol may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Amoxicillin trihydrate (a derivative of Amoxicillin) is reported as an ingredient of Amoxibol in the following countries:
International Drug Name Search
Metronidazol Ovulos may be available in the countries listed below.
Metronidazole is reported as an ingredient of Metronidazol Ovulos in the following countries:
International Drug Name Search
In the US, RiaSTAP (fibrinogen systemic) is a member of the drug class miscellaneous coagulation modifiers and is used to treat Congenital Fibrinogen Deficiency.
US matches:
Fibrinogen, human is reported as an ingredient of RiaSTAP in the following countries:
International Drug Name Search
Guardian may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Ivermectin is reported as an ingredient of Guardian in the following countries:
Moxidectin is reported as an ingredient of Guardian in the following countries:
Praziquantel is reported as an ingredient of Guardian in the following countries:
Pyrantel embonate (a derivative of Pyrantel) is reported as an ingredient of Guardian in the following countries:
International Drug Name Search
Orphenadrine Citrate Injection is a sterile aqueous solution of orphenadrine citrate. It is intended for intravenous or intramuscular administration.
Orphenadrine citrate is the citrate salt of orphenadrine and occurs as a white, crystalline powder having a bitter taste. It is practically odorless, sparingly soluble in water and slightly soluble in alcohol. It has the following structural formula:
N,N-Dimethyl-2-[(o-methyl-α-phenylbenzyl)oxy]ethylamine Citrate (1:1).
Each mL contains: Orphenadrine Citrate 30 mg, Sodium Metabisulfite 0.91 mg, Sodium Chloride 2.9 mg, in Water for Injection q.s. Sodium Hydroxide and/or Hydrochloric Acid may have been used to adjust pH.
The mode of action has not been clearly identified but may be related to analgesic properties. Orphenadrine citrate possesses anticholinergic actions.
Orphenadrine citrate is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculo-skeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its analgesic properties. Orphenadrine citrate does not directly relax tense skeletal muscles in man.
Orphenadrine citrate is contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction at the bladder neck, cardiospasm (megaesophagus) and myasthenia gravis.
Orphenadrine citrate is contraindicated in patients who have demonstrated a previous hypersensitivity to the drug.
Contains Sodium Metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
Some patients may experience transient episodes of lightheadedness, dizziness or syncope.
Orphenadrine citrate may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; ambulatory patients should therefore be cautioned accordingly.
Safe use of orphenadrine citrate has not been established with respect to adverse effects upon fetal development. Therefore, orphenadrine citrate should be used in women of childbearing potential and particularly during early pregnancy only when in the judgment of the physician the potential benefits outweigh the possible hazards.
Safety and effectiveness in children have not been established; therefore, this drug is not recommended for use in the pediatric age group.
Confusion, anxiety and tremors have been reported in few patients receiving propoxyphene and orphenadrine concomitantly. As these symptoms may be simply due to an additive effect, reduction of dosage and/or discontinuation of one or both agents is recommended in such cases.
Orphenadrine citrate should be used with caution in patients with cardiac decompensation, coronary insufficiency, cardiac arrhythmias, and tachycardia.
Safety of continuous long term therapy with orphenadrine citrate has not been established. Therefore if orphenadrine citrate is prescribed for prolonged use, periodic monitoring of blood, urine, and liver function values is recommended.
Adverse effects of orphenadrine citrate are mainly due to the mild anticholinergic action, and are usually associated with higher dosage. Dryness of the mouth is usually the first adverse effect to appear. When the daily dose is increased, possible adverse effects include: tachycardia, palpitation, urinary hesitancy or retention, blurred vision, dilatation of pupils, increased ocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness, hypersensitivity reactions, pruritus, hallucinations, agitation, tremor, gastric irritation, and rarely urticaria and other dermatoses. Infrequently, an elderly patient may experience some degree of mental confusion. These adverse reactions can usually be eliminated by reduction in dosage. Very rare cases of aplastic anemia associated with the use of orphenadrine tablets have been reported. No causal relationship has been established.
Rare instances of anaphylactic reaction have been reported associated with the intramuscular injection of orphenadrine citrate.
Adults: 2 mL (60 mg) intravenously or intramuscularly - May be repeated every 12 hours. Relief may be maintained by one (100 mg) orphenadrine citrate tablet twice daily.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever the solution and container permit.
Orphenadrine Citrate Injection USP, 30 mg/mL is available in 2 mL ampules in cartons of 10.
Store at 20º-25ºC (68º-77ºF) [See USP controlled room temperature.]PROTECT FROM LIGHT. DO NOT USE IF PRECIPITATE OCCURS.
Literature revised: June 2010
Product No.: 1108-82
Mfd. by: Hikma Farmaceutica
(Portugal) S.A. 2705-906 Terrugem SNT, Portugal
Dist. by Watson Pharma, Inc.
Corona, CA 92880 USA
PRINCIPAL DISPLAY PANEL
NDC 0591-3222-47
10 x 2mL Sterile Ampules
60 mg/ 2mL
(30 mg/mL)
Orphenadrine
Citrate
Injection USP
60 mg/ 2 mL (30 mg/mL)
FOR INTRAVENOUS OR INTRAMUSCULAR USE
Watson Rx only
| ORPHENADRINE CITRATE orphenadrine citrate injection | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| ANDA | ANDA084779 | 07/08/2010 | |
| Labeler - Watson Laboratories, Inc. (023932721) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| Hikma Farmaceutica | 452742943 | ANALYSIS, LABEL, MANUFACTURE, PACK | |
Relieving symptoms of an unproductive cough and mucus in the chest due to colds, flu, or hay fever. It may also be used for other conditions as determined by your doctor.
Organidin NR Liquid is an expectorant. It works by thinning mucus (phlegm) in the lungs and making it less sticky and easier to cough up. This reduces chest congestion by making coughs more productive.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Organidin NR Liquid. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Organidin NR Liquid. Tell your health care provider if you are taking any other medicines. However, no specific interactions with Organidin NR Liquid are known at this time.
Ask your health care provider if Organidin NR Liquid may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Organidin NR Liquid as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Organidin NR Liquid.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Nausea; vomiting.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Organidin NR side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.
Store Organidin NR Liquid at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Organidin NR Liquid out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Organidin NR Liquid. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Definition of Echinococcus: A tissue infection by the larval stage of the Echinococcus granulosus worm. This disease is common in South America, the Middle East, Asia and Africa. Sporadic cases have been reported in the us. Infection occurs after ingestion of eggs in infected dog faeces. The infection is carried to the liver where cysts form. Cysts may also form in the lungs, bone, brain, kidney, muscles and spleen.Symptoms include abdominal pain, itching, cough, haemoptysis, chest pain and fever. Treatment includes the surgical removal of cysts from the tissue. More...
The following drugs and medications are in some way related to, or used in the treatment of Echinococcus. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Medical Encyclopedia:
Anthraxiton may be available in the countries listed below.
Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Anthraxiton in the following countries:
International Drug Name Search
Auréomycine Evans may be available in the countries listed below.
Chlortetracycline hydrochloride (a derivative of Chlortetracycline) is reported as an ingredient of Auréomycine Evans in the following countries:
International Drug Name Search
Ampidog may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Ampicillin trihydrate (a derivative of Ampicillin) is reported as an ingredient of Ampidog in the following countries:
International Drug Name Search
Dixi 35 may be available in the countries listed below.
Cyproterone is reported as an ingredient of Dixi 35 in the following countries:
Ethinylestradiol is reported as an ingredient of Dixi 35 in the following countries:
International Drug Name Search
Tearbalance may be available in the countries listed below.
Hyaluronic Acid sodium salt (a derivative of Hyaluronic Acid) is reported as an ingredient of Tearbalance in the following countries:
International Drug Name Search
Fragivix may be available in the countries listed below.
Benzarone is reported as an ingredient of Fragivix in the following countries:
International Drug Name Search
Evercil may be available in the countries listed below.
Phenylephrine hydrochloride (a derivative of Phenylephrine) is reported as an ingredient of Evercil in the following countries:
International Drug Name Search
Diuver may be available in the countries listed below.
Torasemide is reported as an ingredient of Diuver in the following countries:
International Drug Name Search
Hydrocortison Jenapharm may be available in the countries listed below.
Hydrocortisone is reported as an ingredient of Hydrocortison Jenapharm in the following countries:
International Drug Name Search
Carvedilol Adico may be available in the countries listed below.
Carvedilol is reported as an ingredient of Carvedilol Adico in the following countries:
International Drug Name Search
